J&J is one of only two U.S. corporations with a AAA credit rating and has paid increasing dividends for 62 consecutive years. Its story includes the Tylenol poisoning crisis, the talc litigation, and a landmark corporate split.
Educational content only — not personalized financial, legal, or tax advice.
Johnson & Johnson was founded in 1886 in New Brunswick, New Jersey by three brothers — Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson — to manufacture ready-made surgical dressings. The founding insight was simple but consequential: Lister's germ theory of infection had just been established, and sterile surgical supplies could prevent the deaths that were then common from post-surgical infection. J&J was a healthcare company before most people understood what that meant.
The company's longevity is a function of a corporate structure that has proven remarkably adaptive: a decentralized operating model with hundreds of semi-autonomous business units, a balance sheet managed conservatively for most of its history, and a brand built over generations on trust. Trust is the operative word. J&J's most famous crisis — the 1982 Tylenol poisonings, in which someone laced Extra Strength Tylenol capsules with cyanide, killing seven people in Chicago — also produced what is still taught as the textbook example of crisis management. J&J immediately pulled 31 million bottles from shelves, cooperated fully with authorities, and pioneered tamper-resistant packaging. The brand recovered. The company emerged from the crisis with its reputation enhanced.
For most of its history, Johnson & Johnson operated across three distinct segments, each large enough to be a standalone Fortune 500 company:
Consumer (now separated as Kenvue): Over-the-counter brands including Tylenol, Band-Aid, Neutrogena, Listerine, and Johnson's Baby. These are the products most people associate with the J&J name. This segment was spun off as an independent public company (Kenvue) in 2023 — a strategic choice reflecting that consumer healthcare and pharmaceutical businesses have different capital needs, investor bases, and growth profiles.
Pharmaceutical (Innovative Medicine): Prescription drugs are J&J's growth engine and highest-margin business. The blockbuster immunology drug Stelara (ustekinumab) peaked at over $10 billion in annual sales before biosimilar competition. Darzalex (daratumumab) for multiple myeloma and Tremfya for plaque psoriasis are newer drivers. J&J's oncology and immunology pipelines are among the most productive in the industry.
MedTech: Surgical instruments, orthopedic devices, cardiovascular products, and vision care. The acquisition of Abiomed (heart pump technology) and the pending acquisition of Shockwave Medical (intravascular lithotripsy) expand its cardiovascular footprint.
Johnson & Johnson's most consequential ongoing legal and reputational challenge involves talc-based products — specifically, whether its baby powder caused ovarian cancer and mesothelioma in some users. Tens of thousands of lawsuits have been filed. Internal documents showed that J&J was aware of trace asbestos contamination in some talc samples for decades while publicly asserting the products were safe.
J&J used the "Texas Two-Step" bankruptcy maneuver — spinning off a subsidiary to absorb the talc liability and placing that subsidiary into bankruptcy — in an attempt to settle claims at a discount. Courts have challenged this approach multiple times. The financial exposure is potentially in the tens of billions of dollars, and the litigation has become a significant governance and reputational issue for the company.
J&J is one of only two U.S. companies (with Microsoft) that held a AAA credit rating from S&P as of 2024 — reflecting a balance sheet and cash flow profile that is genuinely exceptional. Revenue runs approximately $85-90 billion annually post-Kenvue spinoff. Net income consistently exceeds $15 billion. The company has increased its dividend for over 60 consecutive years — a Dividend King status that reflects the durability of healthcare demand regardless of economic cycles.
The Kenvue spinoff was designed to allow both companies to be valued on their own terms — J&J as a pharmaceutical and medtech company trading at pharmaceutical multiples, Kenvue as a consumer staples company. Whether the market properly values the sum of the parts is an ongoing debate among healthcare analysts. See how to read a company's financials and dividend investing explained.
Market capitalization: approximately $640 billion; trailing P/E: approximately 29–31x; latest reported second-quarter sales: $25.3 billion, up 6.6%; 2026 reported-sales outlook: approximately $100.8 billion. These figures reflect market data available on September 14, 2026.
This snapshot is informational, not investment advice. Market prices and valuation multiples change continuously; readers should check the company’s latest filing and current quote before making decisions.